Organization
Rogel Cancer Center, University of Michigan
6 abstracts
Abstract
Patient factors associated with chemotherapy modifications: Results from the Optimal Breast Cancer Chemotherapy Dosing (OBCD) study.Org: Memorial Sloan Kettering Cancer Center, Kaiser Permanente Washington Health Research Institute, Rogel Cancer Center, University of Michigan, The Permanente Medical Group Consulting Services, Kaiser Permanente Division of Research,
Abstract
Impact of chemotherapy-induced peripheral neuropathy permanence on patients' preference to discontinue chemotherapy.Org: University of Michigan College of Pharmacy, University of Michigan School of Public Health, Rogel Cancer Center, University of Michigan, Department of Biostatistics, University of Michigan,
Abstract
Patient characteristics associated with primary prophylactic granulocyte colony-stimulating factor (G-CSF) use among women treated for early-stage breast cancer.Org: Memorial Sloan Kettering Cancer Center, Kaiser Permanente Washington Health Research Institute, Rogel Cancer Center, University of Michigan, The Permanente Medical Group Consulting Services, Kaiser Permanente Division of Research,
Abstract
Lenvatinib plus pembrolizumab (L+P) vs sunitinib (S) in advanced renal cell carcinoma (aRCC): Patterns of progression and subsequent therapy in the CLEAR trial.Org: University Hospital Essen, Memorial Sloan Kettering Cancer Center, Tel-Aviv Sourasky Medical Center/Tel-Aviv University, Department of Urology and Eva Mayr-Stihl Cancer Center, Klinikum Stuttgart, Stuttgart, Germany, Medical University of Vienna,
Abstract
A phase 2 multi-arm study of magrolimab in combination with docetaxel in patients with locally advanced or metastatic solid tumors: ELEVATE Lung and UC.Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Rogel Cancer Center, University of Michigan, Huntsman Cancer Center, Oregon Health and Science University, Hospital Virgen del Rocio, Seville, Spain,
Abstract
NOTOS: A pivotal study of navtemadlin, a first-in-class mouse double minute 2 inhibitor (MDM2i), in patients (pts) with TP53 wild-type (TP53WT) Merkel cell carcinoma (MCC) for whom anti PD-1/L1 therapy has failed.Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, University of Pittsburgh Medical Center, Northwestern University, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Rogel Cancer Center, University of Michigan, Aix-Marseille University CHU Timone,